The anti-fibrotic agent SMP-534 attenuates bleomycin-induced pulmonary fibrosis in hamsters
スポンサーリンク
概要
- 論文の詳細を見る
Pulmonary fibrosis is a progressive and lethal lung disease characterized by accumulation of ECM and loss of pulmonary function. However, no cure exists for this disease, and current treatments often fail to slow its progression or relieve its symptoms. We have previously reported that the anti-fibrotic agent SMP-534 has beneficial effects on renal fibrosis in animal model of nephropathy. In this study, we examined whether SMP-534 has beneficial effects on pulmonary fibrosis in bleomycin-treated hamsters. Treatment with SMP-534 [low dose (70 mg/kg) or high dose (110 mg/kg)] counteracted inhibition of body weight increase induced by bleomycin. In addition, SMP-534 significantly inhibited bleomycin-induced increase in lung hydroxyproline level, an index of collagen formation. Moreover, SMP-534 significantly ameliorated histological pulmonary fibrotic changes induced by bleomycin. The results of this study indicate that the anti-fibrotic agent SMP-534 may offer a new therapeutic option for the treatment of pulmonary fibrosis.
- バイオメディカルリサーチプレスの論文
バイオメディカルリサーチプレス | 論文
- Methylseleninic acid (MSA) inhibits 17β-estradiol-induced cell growth in breast cancer T47D cells via enhancement of the antioxidative thioredoxin/ thioredoxin reductase system
- Expression of human factors CD81, claudin-1, scavenger receptor, and occludin in mouse hepatocytes does not confer susceptibility to HCV entry
- Effect of heat on synthesis of gelatinases and pro-inflammatory cytokines in equine tendinocytes
- Histological observations on the microenvironment of osteolytic bone metastasis by breast carcinoma cell line
- Effect of inducible nitric oxide synthase on apoptosis in Candida-induced acute lung injury